Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 31 December 2025 - 2 January 2026

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed

NEW YORK, January 1, 2026, 21:17 ET — Market closed Cytokinetics, Incorporated shares ended Wednesday up 3.5% at $63.54, the final U.S. trading session of 2025, after markets closed Thursday for the New Year’s Day holiday. The stock has traded between $29.31 and $70.98 over the past 52 weeks, according to market data. New York Stock Exchange The year-end move…
2 January 2026
·····
CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

CRISPR Therapeutics stock (CRSP) slips into 2026 as New Year’s Day shuts Wall Street — what investors watch next

NEW YORK, January 1, 2026, 18:59 ET — Market closed Shares of CRISPR Therapeutics AG ended the last trading session of 2025 down 1.4% at $52.44. U.S. stock markets were closed on Thursday for New Year’s Day, according to the NYSE holiday calendar. StockAnalysis The pullback matters because CRISPR heads into 2026 with its first commercial product still early in…
2 January 2026
········
Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

NEW YORK, January 1, 2026, 16:58 ET — Market closed Axsome Therapeutics shares jumped about 23% in the most recent session on Wednesday after the company said the U.S. Food and Drug Administration accepted its supplemental application for AXS-05 to treat agitation in Alzheimer’s disease and granted the filing priority review. The stock last traded at $182.64, after swinging between…
1 January 2026
····
Regencell Bioscience (RGC) stock slid 8% into the New Year’s Day market shutdown — what’s next

Regencell Bioscience (RGC) stock slid 8% into the New Year’s Day market shutdown — what’s next

NEW YORK, January 1, 2026, 10:46 ET — Market closed. Regencell Bioscience Holdings’ shares last closed down 8.3% at $21 on Wednesday, just before U.S. markets shut for the New Year’s Day holiday. New York Stock Exchange The latest swing underlined the stock’s extreme volatility: Nasdaq data show a 52-week range spanning roughly $0.09 to $83.60. Nasdaq That matters now…
1 January 2026
·····
Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

Cytokinetics (CYTK) stock ends 2025 higher as Myqorzo launch nears — what’s next

NEW YORK, January 1, 2026, 07:56 ET — Market closed Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday. Yahoo Finance The year-end move keeps focus on…
1 January 2026
·····
Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing

Axsome (AXSM) stock jumps after FDA sets April decision date for Alzheimer’s agitation filing

NEW YORK, January 1, 2026, 07:18 ET — Market closed Key points: With U.S. markets closed on Thursday for the New Year’s Day holiday, Axsome Therapeutics shares were last up 22.9% at $182.64 after the company said the FDA granted priority review for its Alzheimer’s disease agitation filing. The stock swung between $148.79 and $184.40 in Wednesday’s session. Volume was…
1 January 2026
····
Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

Axsome stock jumps 23% after FDA sets April 30 deadline for Alzheimer’s agitation review

NEW YORK, January 1, 2026, 03:20 ET — Market closed Axsome Therapeutics Inc shares jumped 22.9% to $182.64 in Wednesday’s session, after touching $184.40, with about 3.1 million shares traded. The CNS drugmaker said the U.S. Food and Drug Administration accepted and granted priority review to its supplemental new drug application for AXS-05 (dextromethorphan-bupropion) — marketed as Auvelity for major…
1 January 2026
···
INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

INBS stock whipsaws after Intelligent Bio Solutions lines up $10 million funding

NEW YORK, January 1, 2026, 03:10 ET — Market closed Intelligent Bio Solutions Inc said late Wednesday it will raise about $10 million in a private placement, sending its shares lower in after-hours trading after a sharp rally earlier in the session. The financing lands as the micro-cap medtech company pitches a faster path to scale for its fingerprint-based drug…
1 January 2026
····
BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

BillionToOne (BLLN) stock slides 4% in thin year-end trade as investors look to January catalysts

NEW YORK, December 31, 2025, 15:27 ET — Regular session. Shares of BillionToOne (BLLN.O) fell about 4% on Wednesday, sliding $3.49 to $81.61 in afternoon trading. The stock has traded between $81.25 and $89.36, with about 243,000 shares changing hands. The move came on the final trading day of 2025, when liquidity is typically thin and price swings can look…
31 December 2025
·····
Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

Cytokinetics stock jumps today as CYTK traders focus on Myqorzo launch and insider filing

NEW YORK, December 31, 2025, 14:52 ET — Regular session Cytokinetics, Incorporated shares rose 3.7% to $63.63 in afternoon trading on Wednesday, after touching $64.40 earlier in the session. The stock traded as low as $60.87, while the S&P 500 tracker and Nasdaq 100 fund were both down about 0.4% to 0.5%. The move matters because Cytokinetics is nearing its…
31 December 2025
·····
Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

Axsome Therapeutics (AXSM) stock jumps 23% after FDA priority review for Alzheimer’s agitation filing

NEW YORK, December 31, 2025, 14:41 ET — Regular session Axsome Therapeutics shares jumped 23% in afternoon trading on Wednesday after the company said U.S. regulators accepted its application and granted a faster review for AXS-05 to treat agitation in Alzheimer’s disease. GlobeNewswire The FDA’s acceptance puts a hard deadline on the next major catalyst for Axsome, with an April…
31 December 2025
·····
INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

INBS stock surges 160% as Intelligent Bio Solutions strikes manufacturing deal targeting 40% cost cuts

NEW YORK, December 31, 2025, 13:04 ET — Regular session Intelligent Bio Solutions Inc shares surged on Wednesday after the company said it struck a new manufacturing partnership aimed at lowering costs for its fingerprint-based drug testing device. The stock was up $6.56, or about 160%, at $10.66 by 1:04 p.m. ET. Google The announcement matters now because Intelligent Bio…
31 December 2025
····
1 … 6 7 8 9 10 … 24

Stock Market Today

  • iShares Short Treasury Bond ETF (SHV) Dips Below 200-Day Moving Average
    February 2, 2026, 12:15 PM EST. Shares of iShares Short Treasury Bond ETF (SHV) fell below their 200-day moving average of $110.29 on Tuesday, dropping to $110.06. This technical indicator, commonly used by traders to assess long-term trends, signals potential shifts in market sentiment. SHV is trading near its 52-week low of $109.91 and below its 52-week high of $110.64, with the latest trade at $110.07. The ETF declined about 0.3% during the session, reflecting modest downward pressure. Such moves are watched closely by investors for clues about short-term momentum and market dynamics in Treasury-related securities.
Go toTop